Galmed Pharmaceuticals (NASDAQ:GLMD) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday.
According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “
GLMD has been the subject of several other reports. Roth Capital assumed coverage on shares of Galmed Pharmaceuticals in a report on Wednesday, November 15th. They issued a “buy” rating and a $32.00 price target for the company. ValuEngine downgraded shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, December 6th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Galmed Pharmaceuticals in a report on Friday, October 27th. Finally, Seaport Global Securities reissued a “buy” rating and issued a $19.00 price target on shares of Galmed Pharmaceuticals in a report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $19.20.
Shares of Galmed Pharmaceuticals (NASDAQ:GLMD) traded down $0.37 during trading hours on Thursday, reaching $11.13. 71,649 shares of the company’s stock traded hands, compared to its average volume of 86,419. Galmed Pharmaceuticals has a 1 year low of $3.85 and a 1 year high of $12.22. The company has a market cap of $175.04, a P/E ratio of -9.12 and a beta of 2.46.
A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. GRT Capital Partners L.L.C. acquired a new stake in shares of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 18,314 shares of the biopharmaceutical company’s stock, valued at approximately $114,000. GRT Capital Partners L.L.C. owned approximately 0.15% of Galmed Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 9.85% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/11/galmed-pharmaceuticals-glmd-downgraded-by-zacks-investment-research-to-hold.html.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.